Of note, recent work demonstrated that the TLR7/8/9 antagonist IMO-8503 improved lean mass retention and decreased muscle catabolism in the Lewis lung carcinoma (LLC) cachexia model, without any changes to tumor size37. This evidence concerns the gene TLR7 and Cachexia.